Double Unit Cord Blood Transplant in Hematologic Malignancies.
Condition(s) studied
Investigational drug(s) / intervention(s)
tranplant: double unit cord blood transplnat
Study summary
The efficacy and safety of non-myeloablative and myeloablative preconditioning followed by dual-unit umbilical cord blood transplantation from unrelated donors in adult patients with malignant hematologic diseases eligible for allogeneic hematopoietic stem cell transplantation are evaluated through prospective observation and analysis of actual clinical data collection
Eligibility
Primary outcome measure(s)
- Overall Survival — 2 years
Trial sites (6)
| Facility | City | Region | Status |
|---|---|---|---|
| Jeonbuk National University Hopital | Jeonju | Jeonlabuk-do | Not Yet Recruiting |
| Keimyung Unversity Dongsan Hospital | Daegu | South Korea | Not Yet Recruiting |
| Dong-A University Hospital | Pusan | South Korea | Not Yet Recruiting |
| Pusan National University Hospital | Pusan | South Korea | Not Yet Recruiting |
| Seoul National University Bundang Hospital | Seongnam | South Korea | Not Yet Recruiting |
| Seoul National University Hospital | Seoul | South Korea | Recruiting |
More Seoul National University Hospital trials in South Korea
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06712108 on ClinicalTrials.gov ↗ ← All trials in South Korea